Can Hand-Foot-Mouth Disease Exacerbate Eczema in Infants?
Yes, hand-foot-mouth disease (HFMD) can significantly exacerbate eczema in infants, manifesting as "eczema coxsackium"—a severe presentation where viral lesions preferentially localize to areas of active or previously affected eczematous skin.
Understanding the Phenomenon
HFMD, particularly when caused by coxsackievirus A6 (CVA6), has a well-documented tendency to worsen in children with underlying atopic dermatitis. In a large case series, 55% of patients with atypical HFMD had eruptions accentuated in areas of eczematous dermatitis, a pattern specifically termed "eczema coxsackium" 1. This represents a distinct clinical entity where the viral infection exploits the compromised skin barrier characteristic of eczema.
Clinical Presentation to Recognize
When HFMD affects an infant with eczema, expect:
- Vesicular, bullous, and erosive eruptions concentrated on both active and inactive eczematous skin 2
- Distribution beyond classic sites: While typical HFMD affects palms, soles, and buttocks, eczema coxsackium spreads to arms, legs, face, and trunk—essentially wherever eczema has been present 3, 1
- More extensive involvement: 61% of atypical cases involve >10% body surface area 1
- Polymorphic morphology: Lesions may appear as vesicles (53%), papules (49%), or bullae (36%) 3
- Brief febrile prodrome followed by rash development 2
Critical Diagnostic Pitfall
The most dangerous mistake is misdiagnosing eczema coxsackium as eczema herpeticum, which would lead to unnecessary hospitalization and inappropriate acyclovir treatment 3, 4. Key distinguishing features:
- Eczema coxsackium: Vesicles distributed on hands, feet, buttocks, and perioral areas in addition to eczematous sites
- Eczema herpeticum: Typically more monomorphic punched-out erosions concentrated in eczematous areas without the characteristic hand-foot-mouth distribution
CVA6 is identified in 63% of atypical cases 3, and RT-PCR can confirm diagnosis when clinical uncertainty exists.
Management Approach
The condition is self-limiting with excellent prognosis 1, 5. Your management strategy should be:
- Supportive care only: No antiviral therapy needed
- Continue baseline eczema management: Liberal emollients and appropriate topical corticosteroids for the underlying atopic dermatitis 6
- Symptomatic relief: Address fever and discomfort
- Parental counseling: Symptoms resolve in mean of 10 days 3; fever typically resolves within 5-7 days 5
- Anticipatory guidance: Warn about delayed complications occurring 2-3 weeks later:
Why This Matters for Morbidity
While the guidelines note that deterioration in previously stable eczema may be due to secondary bacterial or viral infection 6, they don't specifically address HFMD. However, recognizing this entity prevents:
- Unnecessary hospitalization (16% of reported cases received treatment, mostly inappropriately) 3
- Inappropriate antibiotic or antiviral therapy
- Parental anxiety from misdiagnosis as more serious conditions
- Failure to implement infection control measures (fecal-oral and respiratory droplet transmission) 7
No serious systemic complications occurred in the large case series 1, confirming the benign nature despite dramatic appearance.
Infection Control Imperative
Given that infants with eczema are at higher risk for severe presentation, counsel families on transmission prevention through fecal-oral, oral-oral, and respiratory droplet routes 7. This protects other household members and prevents community spread.